JP7280387B2 - 抗原結合タンパク質 - Google Patents

抗原結合タンパク質 Download PDF

Info

Publication number
JP7280387B2
JP7280387B2 JP2021571490A JP2021571490A JP7280387B2 JP 7280387 B2 JP7280387 B2 JP 7280387B2 JP 2021571490 A JP2021571490 A JP 2021571490A JP 2021571490 A JP2021571490 A JP 2021571490A JP 7280387 B2 JP7280387 B2 JP 7280387B2
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
binding protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021571490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535034A (ja
Inventor
ヤン、ワイ、デゲンハルト
ジュン、グアン
ケネス、ウィリアム、ヘンス
ピーター、ジョセフ、モーリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2022535034A publication Critical patent/JP2022535034A/ja
Priority to JP2023078141A priority Critical patent/JP7546723B2/ja
Application granted granted Critical
Publication of JP7280387B2 publication Critical patent/JP7280387B2/ja
Priority to JP2024139180A priority patent/JP2024167261A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021571490A 2019-09-27 2020-09-25 抗原結合タンパク質 Active JP7280387B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023078141A JP7546723B2 (ja) 2019-09-27 2023-05-10 抗原結合タンパク質
JP2024139180A JP2024167261A (ja) 2019-09-27 2024-08-20 抗原結合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906876P 2019-09-27 2019-09-27
US62/906,876 2019-09-27
US202063057508P 2020-07-28 2020-07-28
US63/057,508 2020-07-28
PCT/EP2020/076834 WO2021058711A2 (en) 2019-09-27 2020-09-25 Antigen binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023078141A Division JP7546723B2 (ja) 2019-09-27 2023-05-10 抗原結合タンパク質

Publications (2)

Publication Number Publication Date
JP2022535034A JP2022535034A (ja) 2022-08-04
JP7280387B2 true JP7280387B2 (ja) 2023-05-23

Family

ID=72840475

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021571490A Active JP7280387B2 (ja) 2019-09-27 2020-09-25 抗原結合タンパク質
JP2023078141A Active JP7546723B2 (ja) 2019-09-27 2023-05-10 抗原結合タンパク質
JP2024139180A Pending JP2024167261A (ja) 2019-09-27 2024-08-20 抗原結合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023078141A Active JP7546723B2 (ja) 2019-09-27 2023-05-10 抗原結合タンパク質
JP2024139180A Pending JP2024167261A (ja) 2019-09-27 2024-08-20 抗原結合タンパク質

Country Status (16)

Country Link
US (2) US11479607B2 (https=)
EP (1) EP4034562B1 (https=)
JP (3) JP7280387B2 (https=)
KR (1) KR20220070011A (https=)
CN (2) CN114729049B (https=)
AU (1) AU2020355614B2 (https=)
BR (1) BR112022005787A2 (https=)
CA (1) CA3155173A1 (https=)
CO (1) CO2022003053A2 (https=)
ES (1) ES3053994T3 (https=)
IL (1) IL291364A (https=)
MX (1) MX2022003523A (https=)
MY (1) MY207830A (https=)
PH (1) PH12022550671A1 (https=)
TW (1) TWI865617B (https=)
WO (1) WO2021058711A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530267A (ja) 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌及びウイルス感染症を治療するための免疫受容体調節
JP2016530268A (ja) 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌及びウイルス感染症を治療するための免疫受容体調節
WO2018129346A1 (en) 2017-01-06 2018-07-12 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
WO2019030377A1 (en) 2017-08-11 2019-02-14 Blink Biomedical Sas CD96 BINDING AGENTS AS IMMUNOMODULATORS

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
CA2417806C (en) 2000-08-04 2011-05-10 Corixa Corporation New immunoeffector compounds
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CA2809089C (en) 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
EP3147297B1 (en) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
CA2845810C (en) 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
HK1210964A1 (en) 2012-12-04 2016-05-13 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
MD4733C1 (ro) * 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CN110914304B (zh) 2017-11-10 2022-07-26 江苏恒瑞医药股份有限公司 Cd96抗体、其抗原结合片段及医药用途
TWI877769B (zh) * 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
WO2021058711A2 (en) * 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016530267A (ja) 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌及びウイルス感染症を治療するための免疫受容体調節
JP2016530268A (ja) 2013-08-22 2016-09-29 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 癌及びウイルス感染症を治療するための免疫受容体調節
WO2018129346A1 (en) 2017-01-06 2018-07-12 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
WO2019030377A1 (en) 2017-08-11 2019-02-14 Blink Biomedical Sas CD96 BINDING AGENTS AS IMMUNOMODULATORS

Also Published As

Publication number Publication date
JP2023103352A (ja) 2023-07-26
CN114729049B (zh) 2024-10-25
CN119431581A (zh) 2025-02-14
IL291364A (en) 2022-05-01
JP7546723B2 (ja) 2024-09-06
TWI865617B (zh) 2024-12-11
AU2020355614A1 (en) 2022-04-14
MY207830A (en) 2025-03-21
US12528864B2 (en) 2026-01-20
JP2024167261A (ja) 2024-12-03
CN114729049A (zh) 2022-07-08
BR112022005787A2 (pt) 2022-06-21
US20230279106A1 (en) 2023-09-07
AU2020355614B2 (en) 2024-12-05
WO2021058711A2 (en) 2021-04-01
PH12022550671A1 (en) 2023-05-29
EP4034562A2 (en) 2022-08-03
KR20220070011A (ko) 2022-05-27
EP4034562C0 (en) 2025-10-29
CO2022003053A2 (es) 2022-04-19
CA3155173A1 (en) 2021-04-01
US20220089728A1 (en) 2022-03-24
US11479607B2 (en) 2022-10-25
WO2021058711A3 (en) 2021-06-03
MX2022003523A (es) 2022-04-25
ES3053994T3 (en) 2026-01-28
TW202128755A (zh) 2021-08-01
EP4034562B1 (en) 2025-10-29
JP2022535034A (ja) 2022-08-04

Similar Documents

Publication Publication Date Title
CN108025051B (zh) 包含抗pd-1抗体分子的联合疗法
CN107001478B (zh) 针对pd-l1的抗体分子及其用途
JP2021521182A (ja) Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療
KR20180088907A (ko) Pd-1에 대한 항체 분자 및 그의 용도
JP2018523652A (ja) Ｐｄ−１アンタゴニストとｅｇｆｒ阻害剤の組み合わせ物
AU2021207348A1 (en) Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
JP2024167261A (ja) 抗原結合タンパク質
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
JP2022524921A (ja) がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン
US20240166747A1 (en) Antigen binding proteins and combinations thereof
RU2827188C1 (ru) Антигенсвязывающие белки
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
HK40091842A (zh) 用於癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
EA040861B1 (ru) Молекулы антител к pd-l1 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230511

R150 Certificate of patent or registration of utility model

Ref document number: 7280387

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350